Cancer Network’s FACE-OFF examines the evolving role of cereblon E3 ligase modulators, or CELMoDs, in relapsed/refractory multiple myeloma, with a focus on clinical evidence, patient selection, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results